- Home
- IFRX vs BMEA Comparison
IFRX vs BMEA Comparison
Compare IFRX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- BMEA
- Stock Information
- Founded
- IFRX 2007
- BMEA 2017
- Country
- IFRX Germany
- BMEA United States
- Employees
- IFRX N/A
- BMEA N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- BMEA Health Care
- Exchange
- IFRX Nasdaq
- BMEA Nasdaq
- Market Cap
- IFRX 117.8M
- BMEA 125.4M
- IPO Year
- IFRX 2017
- BMEA 2021
- Fundamental
- Price
- IFRX $1.15
- BMEA $2.16
- Analyst Decision
- IFRX Strong Buy
- BMEA Buy
- Analyst Count
- IFRX 2
- BMEA 12
- Target Price
- IFRX $9.00
- BMEA $28.45
- AVG Volume (30 Days)
- IFRX 337.7K
- BMEA 667.0K
- Earning Date
- IFRX 05-07-2025
- BMEA 05-01-2025
- Dividend Yield
- IFRX N/A
- BMEA N/A
- EPS Growth
- IFRX N/A
- BMEA N/A
- EPS
- IFRX N/A
- BMEA N/A
- Revenue
- IFRX $171,642.00
- BMEA N/A
- Revenue This Year
- IFRX $106.72
- BMEA N/A
- Revenue Next Year
- IFRX $66.89
- BMEA N/A
- P/E Ratio
- IFRX N/A
- BMEA N/A
- Revenue Growth
- IFRX 162.79
- BMEA N/A
- 52 Week Low
- IFRX $1.01
- BMEA $1.87
- 52 Week High
- IFRX $2.82
- BMEA $14.43
- Technical
- Relative Strength Index (RSI)
- IFRX 38.70
- BMEA 33.35
- Support Level
- IFRX $1.01
- BMEA $2.27
- Resistance Level
- IFRX $1.30
- BMEA $2.29
- Average True Range (ATR)
- IFRX 0.13
- BMEA 0.25
- MACD
- IFRX 0.02
- BMEA -0.02
- Stochastic Oscillator
- IFRX 34.15
- BMEA 24.05
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.